Literature DB >> 28475918

Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret).

Yutao Wang1, Yuewen Ding2, Chunguang Yang1, Runfeng Li1, Qiuling Du1, Yanbing Hao1, Zhengtu Li1, Haiming Jiang1, Jin Zhao1, Qiaoyan Chen3, Zifeng Yang4, Zhanlong He5.   

Abstract

Influenza virus infections are the main contagious respiratory disease with high levels of morbidity and mortality worldwide. Antiviral drugs are indispensable for the prophylaxis and treatment of influenza and other respiratory viral infections. In this study, the Arbidol hydrochloride (ARB), which has been licensed in Russia and China, is used to investigate its anti-viral and anti-inflammatory efficacy in vitro and in vivo. The antiviral results in vitro showed that ARB had a better inhibition on Influenza virus A/PR/8/34 (H1N1), A/Guangdong/GIRD07/09 (H1N1), A/Aichi/2/68 (H3N2), A/HK/Y280/97 (H9N2) with IC50 ranging from 4.4 to 12.1μM. The further mechanisms study demonstrated that ARB is able to inhibit hemagglutinin-mediated hemolysis at concentration of 3.91-15.63μg/mL. The anti-inflammatory efficacy in vitro indicated that IL-6, IP-10, MCP-1, RANTES and TNF-α levels were diminished by ARB at concentrations of 22.6 and 18.8μM. The in vivo results in mice model displayed that the survival rates of mice administered 25mg/mL and 45mg/mL ARB were 40% and 50% respectively. And also, ARB can inhibit the decrease of body weight at 45mg/mL and inhibit the increase of mice lung index at 25mg/mL and 45mg/mL comparing to virus group. In ferret model, the ARB-treated ferrets showed a fever that peaked at 2 dpi and gradually decreased beginning at 3 dpi while relatively high temperatures were observed until 4 dpi in the virus group. The ARB-treated group scored 0-1 in the activity level at 2 dpi and 3 dpi at all time points. The transcription levels of cytokines in the respiratory tract of ferrets were detected at 3 dpi. Several proinflammatory cytokines induced by influenza (IL-10, TNF-α, IL-8 and IL-6) were down-regulated by post-treatment with ARB. The histopathological results of ferret lung displayed that ARB can alleviate the influenza virus induced lung lesions. Our results clarified the activity of ARB in both suppressing virus propagation and modulating the expression of inflammatory cytokines in vitro and in vivo, it can be as an effective drug to treat the influenza virus infection.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory; Anti-viral; Arbidol hydrochloride; Influenza virus

Mesh:

Substances:

Year:  2017        PMID: 28475918     DOI: 10.1016/j.biopha.2017.04.091

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  16 in total

Review 1.  Advances in the possible treatment of COVID-19: A review.

Authors:  Pankaj Chibber; Syed Assim Haq; Irfan Ahmed; Nusrit Iqbal Andrabi; Gurdarshan Singh
Journal:  Eur J Pharmacol       Date:  2020-07-17       Impact factor: 4.432

2.  Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means.

Authors:  Olivier Terrier; Anny Slama-Schwok
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Generation of a Reassortant Influenza A Subtype H3N2 Virus Expressing Gaussia Luciferase.

Authors:  Lin Wang; Qinghua Cui; Xiujuan Zhao; Ping Li; Yanyan Wang; Lijun Rong; Ruikun Du
Journal:  Viruses       Date:  2019-07-20       Impact factor: 5.048

4.  The antiviral activity of arbidol hydrochloride against herpes simplex virus type II (HSV-2) in a mouse model of vaginitis.

Authors:  Qiuling Du; Zhen Gu; Irina Leneva; Haiming Jiang; Runfeng Li; Liehua Deng; Zifeng Yang
Journal:  Int Immunopharmacol       Date:  2019-01-03       Impact factor: 4.932

Review 5.  The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control.

Authors:  Yosra A Helmy; Mohamed Fawzy; Ahmed Elaswad; Ahmed Sobieh; Scott P Kenney; Awad A Shehata
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

6.  Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.

Authors:  Jing Chen; Shaowu Lin; Conway Niu; Qi Xiao
Journal:  Expert Rev Respir Med       Date:  2020-09-17       Impact factor: 3.772

7.  Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study.

Authors:  Hong-Dou Chen; Xu Wang; Shu-Le Yu; Yue-Hui Ding; Meng-Lei Wang; Jin-Na Wang
Journal:  Open Forum Infect Dis       Date:  2020-11-18       Impact factor: 3.835

8.  The Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Surface Decoration of Selenium Nanoparticles with β-Thujaplicin through Reactive Oxygen Species-Mediated AKT and p53 Signaling Pathways.

Authors:  Changbing Wang; Haiyang Chen; Danyang Chen; Mingqi Zhao; Zhengfang Lin; Min Guo; Tiantian Xu; Yi Chen; Liang Hua; Tao Lin; Ying Tang; Bing Zhu; Yinghua Li
Journal:  ACS Omega       Date:  2020-11-16

Review 9.  Drug repurposing and cytokine management in response to COVID-19: A review.

Authors:  Luana Heimfarth; Mairim Russo Serafini; Paulo Ricardo Martins-Filho; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior
Journal:  Int Immunopharmacol       Date:  2020-08-31       Impact factor: 4.932

Review 10.  Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics.

Authors:  Ran Chen; Tingting Wang; Jie Song; Daojun Pu; Dan He; Jianjun Li; Jie Yang; Kailing Li; Cailing Zhong; Jingqing Zhang
Journal:  Int J Nanomedicine       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.